Drug Trial Radar · NCT05155020
A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma
Last checked: Nov 19, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Feb 11, 2022
Primary completion
Aug 5, 2022
Study completion Aug 5, 2022
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma.
Conditions
- Asthma
Interventions
AK120Biological
AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.
AK120Biological
AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
AK120Biological
AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
PlaceboBiological
Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1) from baseline at week 12.Time frame: At week 12
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Jingmei General Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Cangzhou People's Hospital
Cangzhou, Hebei, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Luoyang Central Hospital
Luoyang, Henan, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Baogang Hospital, Inner Mongolia, China
Baotou, Inner Mongolia, China
Inner Mongolia People's Hospital
Hohhot, Inner Mongolia, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Jiangxi Provincial Prople's Hospita
Nanchang, Jiangxi, China
Jiangxi Pingxiang People's Hospital
Pingxiang, Jiangxi, China
Jilin Province People's Hospital
Changchun, Jilin, China
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
The Second Affiliated Hospital Zhejiang University School of Medicine,
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.